Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS.
about
Shortened telomere length is associated with increased risk of cancer: a meta-analysisMyeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDSThe association of telomere length and cancer: a meta-analysisLeukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study.NQO1, MPO, and the risk of lung cancer: a HuGE review.Abnormal mRNA Expression Levels of Telomere-Binding Proteins Represent Biomarkers in Myelodysplastic Syndromes: A Case-Control StudyThe genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights.The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanismsThe role of telomere biology in bone marrow failure and other disordersAdvances in the understanding of susceptibility to treatment-related acute myeloid leukaemia.Therapy-related myeloid leukemia.No telomere shortening in marrow stroma from patients with MDS.Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma.Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome.Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpressionClonality in context: hematopoietic clones in their marrow environment.
P2860
Q21135356-69011AA0-2887-4207-93A5-E13EB90019BFQ33733541-E7E6A97C-5EE4-4283-B938-15811ADAB8FEQ34026414-F8871516-7731-4FDB-AFF6-21B50C99A3E4Q35088725-6B06325F-3090-42D2-8BF1-1201BB2C7A24Q36260511-99E49E67-62ED-477C-99BD-351A5BD862BEQ36345275-1341ABF0-56AB-4523-979A-4648103BDDF5Q36415991-F2C91FF6-7766-458A-9D28-8492A10CF6C1Q36500327-47343410-6540-40A4-A2E1-7592C8129F8AQ36516357-7042AFD2-2F9A-4576-9D73-02509C07AB13Q36835902-887FB865-45CD-49D5-B5B9-14F9589687FBQ37009760-8B57BC32-D06E-4BA8-AA58-46DB9635D5C7Q37219621-AA1869C1-68D9-4CF0-83EE-A56221025DEEQ37548821-9364D169-23CB-4539-988C-FDA6DD31051EQ37855227-B3846D6F-BD76-4D64-BF8B-4E6CAE613419Q38881049-D393C571-36BF-437D-B032-87E381546BD0Q40039599-66C91A49-8B88-4615-B44B-B9183CC68E17Q41312128-A2BE14C7-5110-4DB8-BEAF-CE2D1CFBFED2Q50091222-1A0BB0CA-C8C9-4937-9B8F-DBFB6EA00201
P2860
Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Clonal haemopoiesis may occur ...... n increased risk of t-AML/MDS.
@en
Clonal haemopoiesis may occur ...... n increased risk of t-AML/MDS.
@nl
type
label
Clonal haemopoiesis may occur ...... n increased risk of t-AML/MDS.
@en
Clonal haemopoiesis may occur ...... n increased risk of t-AML/MDS.
@nl
prefLabel
Clonal haemopoiesis may occur ...... n increased risk of t-AML/MDS.
@en
Clonal haemopoiesis may occur ...... n increased risk of t-AML/MDS.
@nl
P2093
P2860
P1476
Clonal haemopoiesis may occur ...... n increased risk of t-AML/MDS.
@en
P2093
G Ian Carter
Jennifer Byrne
Lorna Fern
Monica Pallis
Nigel Russell
P2860
P356
10.1111/J.1365-2141.2004.05006.X
P407
P577
2004-07-01T00:00:00Z